ZA202400149B - Rna adsorbed onto lipid nano-emulsion particles and its formulations. - Google Patents

Rna adsorbed onto lipid nano-emulsion particles and its formulations.

Info

Publication number
ZA202400149B
ZA202400149B ZA2024/00149A ZA202400149A ZA202400149B ZA 202400149 B ZA202400149 B ZA 202400149B ZA 2024/00149 A ZA2024/00149 A ZA 2024/00149A ZA 202400149 A ZA202400149 A ZA 202400149A ZA 202400149 B ZA202400149 B ZA 202400149B
Authority
ZA
South Africa
Prior art keywords
formulations
emulsion particles
adsorbed onto
lipid nano
rna
Prior art date
Application number
ZA2024/00149A
Other languages
English (en)
Inventor
Sunil Raut
Sanjay Singh
Swarnendu Kaviraj
Ajay Singh
Arjun Singh Raghuwanshi
Pavan Kardile
Shalu Shukla
Aishwarya Kulkarni
Praveen Agrawal
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of ZA202400149B publication Critical patent/ZA202400149B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2024/00149A 2021-07-13 2024-01-03 Rna adsorbed onto lipid nano-emulsion particles and its formulations. ZA202400149B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202121031414A IN202121031414A (enExample) 2021-07-13 2021-07-13
PCT/IN2022/050624 WO2023286076A1 (en) 2021-07-13 2022-07-08 Rna adsorbed onto lipid nano-emulsion particles and its formulations.

Publications (1)

Publication Number Publication Date
ZA202400149B true ZA202400149B (en) 2024-08-28

Family

ID=84920187

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/00149A ZA202400149B (en) 2021-07-13 2024-01-03 Rna adsorbed onto lipid nano-emulsion particles and its formulations.

Country Status (11)

Country Link
US (1) US20240325522A1 (enExample)
EP (1) EP4351521A4 (enExample)
JP (1) JP2024525709A (enExample)
KR (1) KR20240035836A (enExample)
AU (1) AU2022310435A1 (enExample)
CA (1) CA3226213A1 (enExample)
CL (1) CL2024000120A1 (enExample)
CO (1) CO2024000205A2 (enExample)
IN (1) IN202121031414A (enExample)
WO (1) WO2023286076A1 (enExample)
ZA (1) ZA202400149B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021194672A1 (en) 2020-03-23 2021-09-30 Hdt Bio Corp. Compositions and methods for delivery of rna
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
WO2023049636A2 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Cancer therapy compositions and uses thereof
JP2024535352A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023094713A2 (en) * 2021-11-29 2023-06-01 BioNTech SE Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024261766A1 (en) * 2023-06-23 2024-12-26 Gennova Biopharmaceuticals Ltd. Lyophilised vaccine formulation
EP4734962A1 (en) * 2023-06-29 2026-05-06 RIGImmune Inc. Novel formulations
WO2026093528A1 (en) * 2024-10-31 2026-05-07 Etherna Immunotherapies Nv A purification of rna by flowthrough chromatography

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636410B2 (en) * 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
AU2018285694B2 (en) * 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof

Also Published As

Publication number Publication date
IN202121031414A (enExample) 2023-01-13
EP4351521A4 (en) 2025-12-10
CL2024000120A1 (es) 2024-08-16
AU2022310435A1 (en) 2024-01-25
KR20240035836A (ko) 2024-03-18
CO2024000205A2 (es) 2024-01-25
US20240325522A1 (en) 2024-10-03
EP4351521A1 (en) 2024-04-17
CA3226213A1 (en) 2023-01-19
JP2024525709A (ja) 2024-07-12
WO2023286076A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
WO2019125011A3 (ko) 금속-유기 골격체 및 나노셀룰로오스를 이용한 경피전달용 복합체
WO2010138837A3 (en) Nanodiamond particle complexes
EP4635481A3 (en) Biodegradable lipids for the delivery of active agents
MX2019005470A (es) Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm.
MX2024008101A (es) Formulaciones de nanoparticulas lipidicas para componentes de cas/crispr.
ZA202101465B (en) Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
MA43327A1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et d'autres cancers
MX2019005287A (es) Lipidos cationicos para suministro de acido nucleico y su preparacion.
MX2019003005A (es) Formulaciones que contienen lipidos.
EP4481047A3 (en) Biodegradable lipids for the delivery of active agents
MA41393A1 (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
PH12021550303A1 (en) Superabsorbent materials and methods of making the same
EP3916091A3 (en) Dry powder composition comprising long-chain rna
EP2481409A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2007110422A3 (en) Whey protein vehicle for active agent delivery
ATE395907T1 (de) Stabile perlen aus lipophilen nährstoffen
WO2010065329A3 (en) Nanoparticles for cancer treatment
CL2024000120A1 (es) Arn adorbido sobre partículas de nanoemulsión lipídica y sus formulaciones.
MX368106B (es) Formulaciones liquidas de st-246 y metodos.
MX2009011493A (es) Complejo de excipiente farmaceutico.
MX2023003230A (es) Procesos e intermediario para la preparacion a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbon il)-piridin-2-il]-benzamida y preparacion de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il ]-benzamida.
PH12014502429A1 (en) Stabilized formulations containing anti-dll4 antibodies
WO2019078698A3 (ko) 항 -msln항체 및 이를포함하는 암치료용 약학적 조성물
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
SG10201802129QA (en) A pharmaceutical composition for neuropathic pain